August 4, 2011Journal of Cardiovascular Pharmacology and Therapeutics
Development of an NIH Consortium for PreclinicAl AssESsment of CARdioprotective Therapies (CAESAR): A Paradigm Shift in Studies of Infarct Size Limitation
Population
Preclinical models of myocardial infarction (anesthetized mouse, conscious rabbit, and conscious pig)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Rigorous preclinical testing infrastructure may aid translation; leaves open impact on clinical cardioprotection trials.
Structured PICO
P
Population
Preclinical models of myocardial infarction (anesthetized mouse, conscious rabbit, and conscious pig)
I
Intervention
Cardioprotective therapies
O
Outcome
Infarct size limitationsurrogate
The CAESAR consortium provides a rigorous, multicenter infrastructure for preclinical testing of cardioprotective therapies to improve their translation into clinical practice.
Cite This Study
Lefer et al. (2011) studied this question.